Clinical Trials Logo

Post-kala-azar Dermal Leishmaniasis clinical trials

View clinical trials related to Post-kala-azar Dermal Leishmaniasis.

Filter by:
  • None
  • Page 1

NCT ID: NCT03311607 Completed - Clinical trials for Post-kala-azar Dermal Leishmaniasis

Safety and Effectiveness of Short-course AmBisome in the Treatment of PKDL in Bangladesh

Start date: April 8, 2014
Phase: Phase 4
Study type: Interventional

The safety and effectiveness of AmBisome 15 mg/kg, given over 15 days in 5 biweekly infusions of 3 mg/kg on an outpatient basis, is evaluated in clinically diagnosed PKDL patients of 12 years and older in a highly endemic area in Bangladesh. This is a prospective study, with the objective to assess final cure 12 months after treatment.

NCT ID: NCT02193022 Recruiting - Clinical trials for Post Kala Azar Dermal Leishmaniasis

Miltefosine for Children With PKDL

Start date: July 2014
Phase: Phase 3
Study type: Interventional

Hypothesis: Primary hypothesis: 1. Oral treatment with Miltefosine in children with PKDL at allometric daily dose (based on body weight and height) for 12 weeks is safe with a cure rate of ≥95%. Secondary hypothesis: 2. Development of PKDL in children and adolescent is genetically predisposed and is associated with IL-10 & IFN-gamma gene polymorphism causing high and low serum level of IL-10 and IFN-gamma respectively. 3. Nutritional & environmental factors such as low serum vitamin E, A, D, Zn & arsenic exposure are associated with PKDL.

NCT ID: NCT01975051 Completed - Clinical trials for Post-kala-azar Dermal Leishmaniasis

A Study to Explore Association of Treatment Regimens for Visceral Leishmaniasis, Host Immunological, Genetical and Nutrition Factors With Post-kala-azar Dermal Leishmaniasis (PKDL)

Start date: January 2013
Phase: Phase 4
Study type: Interventional

We hypothesize that PKDL develop after SSG as well as after Miltefosine mono-therapy for VL; anti-inflammatory cytokines such as IL-10, TGF-β, serum lipids play key role for its pathogenesis & PKDL patients are genetically predisposed; diagnostic tool based on immunofluorescence technique will be more sensitive than slit skin examination for diagnosis of PKDL.

NCT ID: NCT00982774 Completed - Clinical trials for Post Kala Azar Dermal Leishmaniasis

Safety and Immunogenicity of the LEISH-F2 + MPL-SE Vaccine With SSG for Patients With PKDL

Start date: April 2009
Phase: Phase 1
Study type: Interventional

A phase 1, randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, and immunogenicity of three injections of 10 µg LEISH-F2 + 25 µg MPL-SE given at 14-day intervals as an adjunct to standard chemotherapy with sodium stibogluconate (20 mg/kg/day for 40 days) in patients with PKDL.

NCT ID: NCT00486382 Completed - Clinical trials for Visceral Leishmaniasis

Open-Label Safety Study of Three-Antigen Leishmania Polyprotein With Adjuvant MPL-SE in Healthy Adults in India

Start date: April 2007
Phase: Phase 1
Study type: Interventional

The purpose of this study is to determine if a vaccine (called Leish-111f + MPL-SE) is safe and whether it can or cannot produce a protective response against visceral leishmaniasis when injected to healthy subjects.